Show simple item record

dc.contributor.authorValla, Marit
dc.contributor.authorEngstrøm, Monica J
dc.contributor.authorYtterhus, Borgny
dc.contributor.authorHansen, Åse Kristin Skain
dc.contributor.authorAkslen, Lars A.
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorOpdahl, Signe
dc.contributor.authorBofin, Anna M.
dc.date.accessioned2018-06-13T12:05:27Z
dc.date.available2018-06-13T12:05:27Z
dc.date.issued2017-04
dc.identifier.citationValla M, Engstrøm MJ, Ytterhus B, Hansen ÅKS, Akslen LA, Vatten LJ, Opdahl S, Bofin A M. FGD5 amplification in breast cancer patients is associated with tumor proliferation and a poorer prognosis. Breast Cancer Research and Treatment. 2017;162(2):243-253eng
dc.identifier.urihttp://hdl.handle.net/1956/17793
dc.description.abstract<p>Purpose: Proliferation is a hallmark of cancer. Using a combined genomic approach, FGD5 amplification has been identified as a driver of proliferation in Luminal breast cancer. We aimed to describe FGD5 copy number change in breast cancer, and to assess a possible association with tumour proliferation and prognosis.</p> <p>Methods: We used fluorescence in situ hybridization targeting FGD5 and chromosome 3 centromere (CEP3) on formalin-fixed, paraffin-embedded tissue from 430 primary breast cancers and 108 lymph node metastases, from a cohort of Norwegian breast cancer patients. We tested the association between FGD5 copy number status and proliferation (assessed by Ki67 levels and mitotic count) using Pearson&rsquo;s Chi square test, and assessed the prognostic impact of FGD5 copy number change by estimating cumulative risks of death and hazard ratios.</p> <p>Results: We identified FGD5 amplification (defined as FGD5/CEP3 ratio &ge;2 or mean FGD5/tumour cell &ge;4) in 9.5% of tumours. Mitotic count and Ki67 levels were higher in tumours with FGD5 copy number increase, compared to tumours with no copy number change. After 10 years of follow-up, cumulative risk of death from breast cancer was higher among cases with FGD5 amplification [48.1% (95% CI 33.8&ndash;64.7)], compared to non-amplified cases [27.7% (95% CI 23.4&ndash;32.6)].</p> <p>Conclusions: FGD5 is a new prognostic marker in breast cancer, and increased copy number is associated with higher tumour proliferation and poorer long-term prognosis.</p>eng
dc.language.isoengeng
dc.publisherSpringereng
dc.subjectBreast cancereng
dc.subjectFGD5eng
dc.subjectFISHeng
dc.subjectGene amplificationeng
dc.subjectProliferationeng
dc.subjectPrognosiseng
dc.titleFGD5 amplification in breast cancer patients is associated with tumor proliferation and a poorer prognosiseng
dc.typeJournal articleeng
dc.date.updated2018-01-18T11:20:13Z
dc.rights.holderCopyright 2017 Springer Science+Business Media New Yorkeng
dc.type.versionacceptedVersioneng
bora.peerreviewedPeer reviewedeng
dc.type.documentJournal article
dc.identifier.cristinID1458808
dc.identifier.doi10.1007/s10549-017-4125-8eng
dc.source.issn0167-6806eng
dc.source.issn1573-7217eng
dc.relation.journalBreast Cancer Research and Treatment


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record